Proliferation of breast cancer stem cells via NO/cGMP signaling pathway
| Project/Area Number |
23590322
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
General pharmacology
|
|---|
| Research Institution | National Institute of Health Sciences |
|---|
Principal Investigator |
KANDA Yasunari 国立医薬品食品衛生研究所, 薬理部, 室長 (70510387)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ISHIDA Seiichi 国立医薬品食品衛生研究所, 薬理部第三室, 室長 (10270505)
|
|---|
| Project Period (FY) |
2011 – 2013
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 癌幹細胞 / エストロゲン / NO / cGMP / PKG / 増殖 / 乳癌 / 活性酸素 |
|---|
| Research Abstract |
Growing evidence suggests that development of breast cancer is originated from cancer stem cells, which can be isolated by aldehyde dehydrogenase (ALDH) activity-based flow cytometry analysis. However, the growth regulation of cancer stem cells has not been fully understood. In the present study, we found that estrogen increased the size of ALDH-positive cell population in MCF-7 cells. The effect of estrogen was inhibited by the estrogen receptor (ER) antagonist ICI182780. We next examined the downstream pathway from the ER. A selective NOS inhibitor inhibited the effect of estrogen on NO production and the size of ALDH-positive cell population. In addition, 8-Br-cGMP mimicked the effect of estrogen. Taken together, these data suggest the estrogen expands breast cancer stem cells through the NO/cGMP signaling pathway.
|
Report
(4 results)
Research Products
(64 results)
